𝔖 Bobbio Scriptorium

✦ LIBER ✦

702 PUBLICATION Cetuximab and irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (AIO) is active and safe in the first-line treatment of metastatic colorectal cancer (mCRC) expressing the epidermal growth factor receptor (EGFR)

Book ID: 118623278
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 134 KB
Volume: 3
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(05)80997-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

664 PUBLICATION Cetuximab in combination

664 PUBLICATION Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 137 KB

642 POSTER Cetuximab plus oxaliplatin/5-

642 POSTER Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 268 KB

Cetuximab (C225, Erbitux) in combination

Cetuximab (C225, Erbitux) in combination with irinotecan, infusional 5-fluorouracil (5-FU) and folinic acid (FA) is safe and active in patients (pts) with metastatic colorectal cancer (CRC) expressing epidermal growth factor-receptor (EGFR). Results of a phase I study

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 306 KB

289 Phase II study of cetuximab combined

289 Phase II study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusional 5-FU and folinic acid (FA) in patients (pts) with metastatic, Epidermal growth factor receptor (EGFR)-expressing colorectal cancer (CRC)

✍ J.L. Raoul; J.L. van Laethem; E. Mitry; C. Brezault; F. Husseini; L. Cals; M. Pe 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 170 KB